Leuprorelin acetate
- Createtime： 2026-04-14
- Updatetime： 2026-04-15
Product Details
| useage |
Industrial use
|
| deliveryInfo |
|
| appearance |
White to off-white lyophilized powder/solid
|
| Molecular Weight |
1269.47
|
| Stability |
Stable long-term at -20 ℃, protected from light and sealed; degradable by freeze-thaw cycles; short-term (<24 h) at room temperature needs cold chain protection
|
| aliasen |
|
| supplyCapacity |
50000Metric Ton/Month
|
| Solubility |
Slightly soluble in DMSO, methanol, poor water solubility (requires acidic/buffer solution)
|
| harbor |
Qingdao,China
|
| minorder |
1KG
|
| Molecular Formula |
C 61 ? H 88 ? N 16 ? O 14
|
| Melting Point |
150–155 ℃
|
Purity (HPLC)：
≥98.0% (Research grade ≥98.0%, pharmacopoeial grade ≥99.0%)
Loss on Drying：
≤1.0%
Acetate Content：
In accordance with theoretical value (~11.0–12.0%)
Related Substances：
Single impurity ≤1.0%, total impurities ≤2.0%
Water Content：
≤3.0%
pH (1% Aqueous Solution/Suspension)：
4.5–6.5
Appearance：
White to off-white powder, conforms to standard
Identification (HPLC/MS)：Consistent with reference standard, qualified
-
Core Medical Application
Gonadotropin-releasing hormone (GnRH) agonist, used for palliative treatment of advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and endocrine therapy for premenopausal/estrogen receptor-positive breast cancer. Clinically formulated as long-acting injections (microspheres/implants) with administration intervals of 1–6 months.
-
Research & Reagent Application
As peptide API/biochemical reagent, used for hormonal regulation mechanism research, GnRH receptor function validation, endocrine disease animal model construction, and drug screening.
-
Other Applications
In veterinary medicine for animal reproductive control (e.g., estrus suppression, reproductive efficiency improvement); in assisted reproduction for hormone level regulation.
